Atea Pharmaceuticals Inc. (AVIR)
Atea Pharmaceuticals Statistics
Share Statistics
Atea Pharmaceuticals has 85.53M shares outstanding. The number of shares has increased by 1.55% in one year.
| Shares Outstanding | 85.53M |
| Shares Change (YoY) | 1.55% |
| Shares Change (QoQ) | 1.26% |
| Owned by Institutions (%) | 66.6% |
| Shares Floating | 67.18M |
| Failed to Deliver (FTD) Shares | 629 |
| FTD / Avg. Volume | 0.19% |
Short Selling Information
The latest short interest is 2.97M, so 3.47% of the outstanding shares have been sold short.
| Short Interest | 2.97M |
| Short % of Shares Out | 3.47% |
| Short % of Float | 4.85% |
| Short Ratio (days to cover) | 9.39 |
Valuation Ratios
The PE ratio is -1.68 and the forward PE ratio is -1.75. Atea Pharmaceuticals's PEG ratio is -0.07.
| PE Ratio | -1.68 |
| Forward PE | -1.75 |
| PS Ratio | 0 |
| Forward PS | 9.6 |
| PB Ratio | 0.64 |
| P/FCF Ratio | -2.08 |
| PEG Ratio | -0.07 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Atea Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 24.85, with a Debt / Equity ratio of 0.
| Current Ratio | 24.85 |
| Quick Ratio | 24.85 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-3.01M |
| Employee Count | 56 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -925K |
| Effective Tax Rate | 0.55% |
Stock Price Statistics
The stock price has increased by -20.54% in the last 52 weeks. The beta is 0.17, so Atea Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.17 |
| 52-Week Price Change | -20.54% |
| 50-Day Moving Average | 2.98 |
| 200-Day Moving Average | 3.31 |
| Relative Strength Index (RSI) | 52.08 |
| Average Volume (20 Days) | 335.75K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -192.95M |
| Net Income | -168.38M |
| EBITDA | -192.95M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -2 |
Balance Sheet
The company has 64.7M in cash and 1.64M in debt, giving a net cash position of 63.05M.
| Cash & Cash Equivalents | 64.7M |
| Total Debt | 1.64M |
| Net Cash | 63.05M |
| Retained Earnings | -364.22M |
| Total Assets | 464.67M |
| Working Capital | 443.75M |
Cash Flow
In the last 12 months, operating cash flow was -135.5M and capital expenditures 0, giving a free cash flow of -135.5M.
| Operating Cash Flow | -135.5M |
| Capital Expenditures | 0 |
| Free Cash Flow | -135.5M |
| FCF Per Share | -1.61 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AVIR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for AVIR is $6, which is 104.1% higher than the current price. The consensus rating is "Hold".
| Price Target | $6 |
| Price Target Difference | 104.1% |
| Analyst Consensus | Hold |
| Analyst Count | 1 |
Scores
| Altman Z-Score | 4.57 |
| Piotroski F-Score | 2 |